Hemolytic-Uremic Syndrome (Escherichia coli)
Overview
Plain-Language Overview
Hemolytic-Uremic Syndrome (Escherichia coli) is a serious condition that mainly affects the blood and kidneys. It often occurs after an infection with a specific type of Escherichia coli bacteria that produces harmful toxins. These toxins cause damage to small blood vessels, leading to the destruction of red blood cells and reduced kidney function. The main health problems include anemia, low platelet counts, and kidney failure. Symptoms often start with diarrhea, which can be bloody, followed by fatigue, swelling, and decreased urine output. This condition is most common in children and can require urgent medical care.
Clinical Definition
Hemolytic-Uremic Syndrome (Escherichia coli) is a thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is most commonly caused by infection with Shiga toxin-producing Escherichia coli (STEC), particularly serotype O157:H7. The Shiga toxin damages endothelial cells in small vessels, triggering platelet activation and microthrombi formation, which leads to red blood cell fragmentation and renal ischemia. This syndrome is a leading cause of acute renal failure in children and can result in significant morbidity. The clinical course typically follows a prodrome of bloody diarrhea and abdominal pain. Laboratory findings include elevated lactate dehydrogenase, schistocytes on peripheral smear, and elevated creatinine. Early recognition is critical due to the risk of severe renal and neurological complications.
Inciting Event
Ingestion of Shiga toxin-producing Escherichia coli O157:H7 is the primary trigger.
Preceding bloody diarrhea typically occurs 3-5 days before onset of HUS symptoms.
Contaminated food or water exposure initiates the infectious process.
Contact with infected animals or their environment can also serve as an inciting event.
Latency Period
Typically 3 to 10 days from diarrheal illness onset to development of HUS symptoms.
Hemolytic anemia and thrombocytopenia develop within 1 week after initial gastrointestinal symptoms.
Renal impairment usually manifests within 5 to 7 days after infection.
Diagnostic Delay
Initial attribution of symptoms to common gastroenteritis delays recognition of HUS.
Lack of early laboratory testing for hemolysis and thrombocytopenia can postpone diagnosis.
Failure to recognize the significance of bloody diarrhea preceding renal failure leads to delay.
Misdiagnosis as immune thrombocytopenic purpura or other hematologic disorders may occur.
Clinical Presentation
Signs & Symptoms
Bloody diarrhea preceding onset of hemolytic-uremic syndrome
Fatigue and pallor from anemia
Oliguria or decreased urine output indicating renal impairment
Abdominal pain and vomiting
Bruising or bleeding due to thrombocytopenia
History of Present Illness
Prodromal watery diarrhea progressing to bloody diarrhea is the hallmark initial symptom.
Onset of pallor, fatigue, and decreased urine output follows gastrointestinal symptoms.
Petechiae or purpura due to thrombocytopenia may be reported.
Symptoms of acute kidney injury such as edema and hypertension develop subsequently.
Neurologic symptoms like irritability or seizures can occur in severe cases.
Past Medical History
Recent diarrheal illness within the past 1-2 weeks is a key antecedent event.
No prior history of chronic kidney disease is typical before HUS onset.
Absence of previous hematologic disorders helps differentiate from other thrombotic microangiopathies.
No history of immunosuppressive therapy is common in typical HUS cases.
Family History
Usually no familial pattern as typical HUS is acquired and not inherited.
Rare familial cases linked to complement regulatory gene mutations are associated with atypical HUS, not typical E. coli-associated HUS.
No significant family history of thrombotic microangiopathies is typical in classic HUS.
Physical Exam Findings
Pallor due to anemia from hemolysis
Petechiae and purpura from thrombocytopenia
Hypertension secondary to acute kidney injury
Edema from fluid retention in renal failure
Neurologic signs such as irritability or lethargy in severe cases
Diagnostic Workup
Diagnostic Criteria
Diagnosis of hemolytic-uremic syndrome relies on the presence of the classic triad: microangiopathic hemolytic anemia evidenced by schistocytes on peripheral blood smear, thrombocytopenia, and acute kidney injury with elevated serum creatinine. Confirmation includes detection of Shiga toxin or isolation of Shiga toxin-producing Escherichia coli from stool samples. Additional laboratory tests show elevated lactate dehydrogenase and decreased haptoglobin. The absence of other causes of thrombotic microangiopathy, such as thrombotic thrombocytopenic purpura, supports the diagnosis. Clinical history of recent diarrheal illness, especially bloody diarrhea, further supports the diagnosis.
Pathophysiology
Key Mechanisms
Endothelial injury caused by Shiga toxin-producing Escherichia coli leads to microvascular thrombosis.
Platelet activation and aggregation result in widespread microthrombi formation in small vessels.
Microangiopathic hemolytic anemia occurs due to mechanical destruction of red blood cells passing through occluded vessels.
Acute kidney injury arises from thrombotic microangiopathy affecting renal glomeruli and arterioles.
Complement activation may contribute to endothelial damage and inflammation in some cases.
| Involvement | Details |
|---|---|
| Organs | Kidneys are critically involved with acute renal failure due to thrombotic microangiopathy. |
Bone marrow responds to hemolysis with increased erythropoiesis to compensate for anemia. | |
Gastrointestinal tract is the initial site of Escherichia coli infection and Shiga toxin production. | |
| Tissues | Renal glomerular capillaries are the primary site of microvascular injury causing acute kidney injury. |
Vascular endothelium throughout the body is affected leading to systemic microangiopathic hemolytic anemia. | |
| Cells | Endothelial cells are damaged by Shiga toxin leading to microvascular thrombosis and hemolysis. |
Platelets aggregate at sites of endothelial injury causing microthrombi formation characteristic of the syndrome. | |
Red blood cells undergo mechanical destruction (schistocytes) due to microangiopathic hemolysis. | |
| Chemical Mediators | Shiga toxin produced by Escherichia coli O157:H7 is the primary mediator causing endothelial injury and microangiopathy. |
Von Willebrand factor is released from damaged endothelial cells promoting platelet adhesion and aggregation. | |
Complement activation may contribute to endothelial damage and thrombosis in some cases. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Supportive care with intravenous fluids to maintain hydration and electrolyte balance is essential.
Initiation of renal replacement therapy such as dialysis is indicated in cases of severe acute kidney injury.
Careful blood pressure control to prevent further renal damage is recommended.
Red blood cell transfusions may be necessary to manage severe anemia.
Avoidance of antibiotics and antimotility agents is advised to prevent worsening of toxin release.
Prevention
Pharmacological Prevention
No established antibiotic prophylaxis due to risk of worsening toxin release
Supportive care remains the mainstay to prevent progression
Avoidance of antimotility agents during diarrheal illness to reduce risk
Non-pharmacological Prevention
Strict hand hygiene and food safety to prevent Escherichia coli infection
Avoidance of undercooked meat and unpasteurized dairy products
Public health measures to control contaminated water sources
Prompt hydration during diarrheal illness to reduce risk of HUS
Education on early recognition of bloody diarrhea and seeking medical care
Outcome & Complications
Complications
Severe acute kidney injury requiring dialysis
Neurologic complications including seizures and stroke
Hypertensive encephalopathy
Chronic kidney disease from irreversible renal damage
Cardiac complications such as heart failure from volume overload
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hemolytic-Uremic Syndrome (Escherichia coli) versus Thrombotic Thrombocytopenic Purpura (TTP)
Hemolytic-Uremic Syndrome (Escherichia coli) | Thrombotic Thrombocytopenic Purpura (TTP) |
|---|---|
Primarily affects children under 5 years old | Typically adults aged 20-50 years |
Normal ADAMTS13 activity | Severe ADAMTS13 deficiency (<10%) with large von Willebrand factor multimers |
Often preceded by diarrheal illness with predominant renal failure | Rapid onset with prominent neurological symptoms |
Plasma exchange generally not effective; supportive care preferred | Responds to plasma exchange |
Hemolytic-Uremic Syndrome (Escherichia coli) versus Atypical Hemolytic Uremic Syndrome (aHUS)
Hemolytic-Uremic Syndrome (Escherichia coli) | Atypical Hemolytic Uremic Syndrome (aHUS) |
|---|---|
Often preceded by bloody diarrhea due to Escherichia coli O157:H7 | No preceding diarrheal illness |
Shiga toxin-mediated endothelial damage | Complement-mediated endothelial injury with mutations in complement regulatory genes |
Supportive care; complement inhibitors not routinely used | Improves with complement inhibitors like eculizumab |
Hemolytic-Uremic Syndrome (Escherichia coli) versus Disseminated Intravascular Coagulation (DIC)
Hemolytic-Uremic Syndrome (Escherichia coli) | Disseminated Intravascular Coagulation (DIC) |
|---|---|
Normal or mildly elevated coagulation times, normal fibrinogen | Prolonged PT and aPTT, decreased fibrinogen, elevated D-dimer |
Follows gastrointestinal infection with Shiga toxin-producing E. coli | Associated with sepsis, trauma, or malignancy causing systemic coagulation activation |
Thrombocytopenia with microangiopathic hemolytic anemia without clotting factor consumption | Thrombocytopenia with consumption of clotting factors |
Hemolytic-Uremic Syndrome (Escherichia coli) versus IgA Nephropathy
Hemolytic-Uremic Syndrome (Escherichia coli) | IgA Nephropathy |
|---|---|
Primarily young children under 5 years | Young adults, often teens to 30s |
Hemolytic anemia and thrombocytopenia follow diarrheal illness | Gross hematuria often follows upper respiratory infection |
Hemolytic anemia, thrombocytopenia, and acute kidney injury | Urinalysis shows isolated hematuria with mild proteinuria |
Hemolytic-Uremic Syndrome (Escherichia coli) versus Systemic Lupus Erythematosus (SLE) with Lupus Nephritis
Hemolytic-Uremic Syndrome (Escherichia coli) | Systemic Lupus Erythematosus (SLE) with Lupus Nephritis |
|---|---|
No autoimmune antibodies; negative ANA | Positive ANA and anti-dsDNA antibodies |
Acute onset after infectious diarrhea | Chronic multisystem disease with flares |
Microangiopathic hemolytic anemia with thrombocytopenia and normal complement | Proteinuria with active urinary sediment and low complement levels |